en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Info › Identity And Research Context — Deep Dive

Identity And Research Context — Deep Dive

By Editorial Desk · published 2026-07-19 · last reviewed 2026-08-01 · Info

This is a working overview of lipogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Aod-9604 at a glance

PropertyValueNotes
Common nameAOD-9604Development code used in scientific literature.
Chemical classSynthetic peptideFragment of human growth hormone.
Amino acid length16 residuesMatches hGH region 176-191.
AppearanceWhite to off-white powderTypical lyophilized peptide solid.
SolubilitySoluble in waterDissolves in aqueous media; exact behavior depends on salt form.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Related pages on this site

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Background from the literature

Daveigh Elizabeth Chase ( də-VAY; née Chase-Schwallier; July 24, 1990 – June 16, 2026) was an American actress. Chase began her acting career as a child, portraying Samantha Darko in the psychological thriller film Donnie Darko (2001) and Samara Morgan in the American remake of the horror film The Ring (2002). She also provided the English dub voice of Chihiro Ogino in the Studio Ghibli film Spirited Away (2001) and voiced Lilo Pelekai in the Disney animated film Lilo & Stitch (2002) and its related media franchise. She later took on adult roles, including in the HBO drama series Big Love (2006–2011) and independent films such as Yellow (2012) and Jack Goes Home (2016). Chase received three awards from six nominations, including an Annie Award for Outstanding Achievement for Voice Acting and an MTV Movie Award for Best Villain. Chase retired from acting in 2016 and later died on June 16, 2026 from complications associated with AIDS.

== Use == The thomson has been used by some mass spectrometrists, for example Alexander Makarov—the inventor of the Orbitrap—in a scientific poster, and a 2015 presentation. Other uses of the thomson include papers, and (notably) one book. The journal Rapid Communications in Mass Spectrometry (in which the original article appeared) states that "the thomson (Th) may be used for such purposes as a unit of mass-to-charge ratio although it is not currently approved by IUPAP or IUPAC." Even so, the term has been called "controversial" by RCM's former editor-in-chief (in a review the Hoffman text cited above). The book, Mass Spectrometry Desk Reference, argues against the use of the thomson. However, the editor-in-chief of the Journal of the Mass Spectrometry Society of Japan has written an editorial in support of the thomson unit. The thomson is not an SI unit, nor has it been defined by IUPAC. Since 2013, the thomson is deprecated by IUPAC (Definitions of Terms Relating to Mass Spectrometry). Since 2014, Rapid Communications in Mass Spectrometry regards the thomson as a "term that should be avoided in mass spectrometry publications".

==== Malaysia ==== Most Malaysian think tanks are related either to the government or a political party. Historically they focused on defense, politics and policy. However, in recent years, think tanks that focus on international trade, economics, and social sciences have also been founded. Notable think tanks in Malaysia include:

This scenario usually occurs at very low solidification velocities (< 1 μm s−1) or with extremely fine particles because they can move by Brownian motion away from the front. The resultant structure contains no macroporosity. If one were to increase the solidification speed, the size of the particles or solid loading moderately, the particles begin to interact in a meaningful way with the approaching ice front. The result is typically a lamellar or cellular templated structure whose exact morphology depends on the particular conditions of the system. It is this type of solidification that is targeted for porous materials made by freeze-casting. The third possibility for a freeze-cast structure occurs when particles are given insufficient time to segregate from the suspension, resulting in complete encapsulation of the particles within the ice front. This occurs when the freezing rates are rapid, particle size becomes sufficiently large, or when the solids loading is high enough to hinder particle motion. To ensure templating, the particles must be ejected from the oncoming front. Energetically speaking, this will occur if there is an overall increase in free energy if the particle were to be engulfed (Δσ > 0).

Sources: en.wikipedia.org

Reference notes

Biomedical Sciences Molecular and Cellular Biology Bioengineering and Devices Biophysics, Biochemistry and Structural Biology Climate science, Agriculture and Environment Biotechnology Regulatory Affairs, IPR and Policy

Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid joined by an amide bond. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer. Contrary to previous assumptions that ceramides and other sphingolipids found in cell membrane were purely supporting structural elements, ceramide can participate in a variety of cellular signaling: examples include regulating differentiation, proliferation, and programmed cell death (PCD) of cells. The word ceramide comes from the Latin cera (wax) and amide. Ceramide is a component of vernix caseosa, the waxy or cheese-like white substance found coating the skin of newborn human infants.

This helium-nitrogen mixture was injected and stored in the Cliffside gas field until needed, at which time it was further purified. By 1995, a billion cubic meters of the gas had been collected and the reserve was US$1.4 billion in debt, prompting the Congress of the United States in 1996 to discontinue the reserve. The resulting Helium Privatization Act of 1996 (Public Law 104–273) directed the United States Department of the Interior to empty the reserve, with sales starting by 2005. Helium produced between 1930 and 1945 was about 98.3% pure (2% nitrogen), which was adequate for airships. In 1945, a small amount of 99.9% helium was produced for welding use. By 1949, commercial quantities of Grade A 99.95% helium were available. For many years, the United States produced more than 90% of commercially usable helium in the world, while extraction plants in Canada, Poland, Russia, and other nations produced the remainder. In the mid-1990s, a new plant in Arzew, Algeria, producing 17 million cubic metres (600 million cubic feet) began operation, with enough production to cover all of Europe's demand. Meanwhile, by 2000, the consumption of helium within the U.S. had risen to more than 15 million kg per year. In 2004–2006, additional plants in Ras Laffan, Qatar, and Skikda, Algeria were built. Algeria quickly became the second leading producer of helium. Through this time, both helium consumption and the costs of producing helium increased. From 2002 to 2007 helium prices doubled.

Sources: en.wikipedia.org

Reference notes

On 14 February 2003, the appeals court overturned the verdict, finding that Akre was not a whistleblower because of the Florida "legislature's requirement that agency statements that fit the definition of a "rule" (must) be formally adopted (rules). Recognizing an uncodified agency policy developed through the adjudicative process as the equivalent of a formally adopted rule is not consistent with this policy, and it would expand the scope of conduct that could subject an employer to liability beyond what Florida's Legislature could have contemplated when it enacted the whistle-blower's statute."

== History == Chloroeremomycin was discovered by Eli Lilly in the 1980s. In the 1990s, researchers at Eli Lilly developed biphenyl-chloroeremomycin, now known as oritavancin, as a functionalized derivative of chloroeremomycin to combat rising antibacterial resistance to vancomycin. The chloroeremomycin gene cluster was sequenced by van Wageningen et al in 1998. After the publication, many groups expressed the genes and conducted experiments to understand how chloroeremomycin and, by extension, vancomycin are biosynthesized.

The epineurium is the outermost layer of dense irregular connective tissue surrounding a peripheral nerve. It usually surrounds multiple nerve fascicles as well as blood vessels which supply the nerve. Smaller branches of these blood vessels penetrate into the perineurium. In addition to blood vessels which supply the nerve, lymphocytes and fibroblasts are also present and contribute to the production of collagen fibers that form the backbone of the epineurium. In addition to providing structural support, lymphocytes and fibroblasts also play a vital role in maintenance and repair of the surrounding tissues. When the spinal nerve leaves the vertebral canal via an intervertebral foramen, two layers of the spinal meninges, the arachnoid and the dura invaginate the nerve to form a dural sleeve of connective tissue, which is the epineurium. The outer portion of this sleeve comprises the external epineurium which permits longitudinal nerve excursion and absorption of longitudinal stress. The layer of the epineurium that extends within the nerve to define the fascicles is termed the internal epineurium. Together, these two layers form the epineurium, which varies in thickness along the course of a nerve. The epineurium is usually most abundant around joints, as its function is to protect the nerves from stretching and subsequent injury. Epineurium is primarily made from collagen.

=== Other enterprises === C.P. Company, an Italian apparel brand Cedar Point, an amusement park in Sandusky, Ohio, US Central Partnership, a Russian film distributor and production company Charoen Pokphand (C.P. Group), a Thai agribusiness conglomerate Chicago Pneumatic, an American manufacturer of tools and equipment Colgate-Palmolive, an American consumer goods company Commercial Press, a Chinese publishing company Connaught Place, New Delhi, a commercial centre in India Curious Pastimes, a UK-based gaming company

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Is AOD-9604 the same as human growth hormone?

No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.

Why is it called hGH fragment 176-191?

The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

Network